Life Technologies Expands Line of High-Performance qPCR Instruments
Life Technologies Corporation (NASDAQ: LIFE) today announces further expansion of its qPCR line of instruments with the introduction of two platforms: the QuantStudio™ 7 Flex Real-Time PCR and the QuantStudio™ 6 Flex Real-Time PCR systems. Each provides varying degrees of flexibility designed to match customers' performance and budget needs.
"The launch of these systems provides researchers with much needed application and throughput flexibility with a single instrument," said Chris Linthwaite, President of Genetic Analysis for Life Technologies. "Combined with our recently launched QuantStudio™ 3D Digital PCR System and 510(k)-cleared QuantStudio Dx Real-Time PCR Instrument, this product line now offers flexible solutions across the continuum of basic research to clinical diagnostics."
The QuantStudio™ 7 Flex Real-Time PCR System provides superior flexibility with four interchangeable blocks for experiments requiring either 96-well standard, 96-well fast, 384-well plates or a TaqMan® Array Card (TAC). Throughput is pushed even further with the system's automation capabilities. The new instrument is ideal for maximum multiplexing applications with support for six dyes and 21 filter capabilities.
The QuantStudio™ 6 Flex Real-Time PCR System is the entry-level platform that is competitively priced to enable customers to buy into the product line's high performance and flexibility. It is designed for use with three interchangeable blocks (96-well standard, 96-well fast, or 384-well plates) to fit mid-level throughput needs. As performance requirements increase with larger studies, the instrument can also be upgraded to a QuantStudio™ 7 Flex Real-Time PCR System with the purchase of a kit.
qPCR has long been the workhorse technology used by researchers around the world to detect and decipher genetic variation underlying biological processes, agricultural diversity and human disease. Over 25,000 publications demonstrate the utility and performance of Applied Biosystems® qPCR instruments in gene expression, genotyping, micro RNA, copy number variation and protein analysis experiments.
The new platforms mark the fourth and fifth QuantStudio™ systems introduced by Life Technologies within the last year. Life Technologies first launched the line of instruments with the QuantStudio 12k Flex Real-Time PCR System in 2012. The QuantStudio™ Dx Real-Time PCR Instrument launched in Europe later that year and received FDA clearance for use with Quidel's Clostridium difficile assay in March 2013. Most recently, the company began shipments of the QuantStudio™ 3D Digital PCR System in June.
"The tremendous pace of these new product introductions demonstrates Life Technologies commitment to developing truly innovative platforms designed to support the world's leading scientific work," Linthwaite said. "The QuantStudio 3D instrument sales have already far surpassed our global projections, signifying the value researchers attribute to these new products."
All systems referred to with exception to the QuantStudio™ Dx Real-Time PCR Instrument are for research use only; not intended for diagnostic purposes.
About Life Technologies Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents and licenses that span the entire biological spectrum -- scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012.
Life Technologies' Safe Harbor Statement This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.